Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Alisertib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 15 Feb 2017 Planned End Date changed from 1 Feb 2021 to 1 May 2021.
- 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 20 May 2015 Planned primary completion date changed from 1 Feb 2021 to 1 May 2021 as reported by ClinicalTrials.gov record.